Large‐scale transcriptome profiles reveal robust 20‐signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

Large‐scale transcriptome profiles reveal robust 20‐signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma

Published:2020-06-21 Issue:16 Volume:24 Page:9012-9027
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Xu Wen‐Hao¹²^ORCID,Xu Yue³⁴,Tian Xi¹²^ORCID,Anwaier Aihetaimujiang¹²,Liu Wang‐Rui⁵^ORCID,Wang Jun¹²,Zhu Wen‐Kai¹²,Cao Da‐Long¹²,Wang Hong‐Kai¹²,Shi Guo‐Hai¹²,Qu Yuan‐Yuan¹²,Zhang Hai‐Liang¹²,Ye Ding‐Wei¹²

Affiliation:

1. Department of Urology Fudan University Shanghai Cancer Center Shanghai China

2. Department of Oncology Shanghai Medical CollegeFudan University Shanghai China

3. Department of Ophthalmology First Affiliated Hospital of Soochow University Suzhou China

4. Medical College Soochow University Suzhou China

5. Department of Neurosurgery Affiliated Hospital of Youjiang Medical College for Nationalities Guangxi China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.15536

Reference43 articles.

1. Cancer statistics, 2020

2. Cancer treatment and survivorship statistics, 2019

3. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

4. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

5. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic alterations in hereditary and sporadic renal cell carcinoma;Nature Reviews Nephrology;2024-01-22

2. The FOXO1/G6PC axis promotes gastric cancer progression and mediates 5‐fluorouracil resistance by targeting the PI3K/AKT/mTOR signaling pathway;Molecular Carcinogenesis;2024-01-15

3. Genomic Fabrics of the Excretory System’s Functional Pathways Remodeled in Clear Cell Renal Cell Carcinoma;Current Issues in Molecular Biology;2023-11-24

4. Genetics of enzymatic dysfunctions in metabolic disorders and cancer;Frontiers in Oncology;2023-08-02

5. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma;Journal of Experimental & Clinical Cancer Research;2023-06-10